Ureteral stents: Past, present and future

Expert Review of Medical Devices

Volumn 6, Issue 3, 2009, Pages 313-324

  Liatsikos, Evangelos N ^a   Kallidonis, Panagiotis ^b   Stolzenburg, Jens Uwe ^c   Karnabatidis, Dimitrios ^b  

^a UNIVERSITY OF PATRAS   (Greece)

^b UNIVERSITY OF PATRAS   (Greece)

^c UNIVERSITY OF LEIPZIG   (Germany)

Author keywords

Biodegradable; Drug eluting; Metal stent; Ureteral stent

Indexed keywords

BIOMATERIAL; CHROMIUM; COBALT; EVEROLIMUS; HEPARIN; LIPOSOME; MAGNESIUM; METAL; NITINOL; NITRIC OXIDE; PACLITAXEL; POLYMER; RAPAMYCIN; STAINLESS STEEL; TACROLIMUS; TITANIUM; ZOTAROLIMUS;

BLADDER IRRITATION; CONTROLLED DRUG RELEASE; DRUG DELIVERY SYSTEM; DRUG ELUTING STENT; DYSURIA; FLANK PAIN; HEMATURIA; HUMAN; IN-STENT RESTENOSIS; MATERIAL COATING; MATERIAL STATE; PATIENT SAFETY; REVIEW; TREATMENT INDICATION; URETER OBSTRUCTION; URETER STENT; URETER STONE; URINARY URGENCY; ANIMAL; STENT; URETHRA;

ANIMALS; BIOCOMPATIBLE MATERIALS; HUMANS; STENTS; URETERAL OBSTRUCTION; URETHRA;

EID: 67651065668     PISSN: 17434440     EISSN: 17452422     Source Type: Journal    
DOI: 10.1586/erd.09.5     Document Type: Review

References (124)

1. Lam JS, Gupta M. Update on ureteral stents. Urology 64, 9-15 (2004).
2. Denstedt JD. The endourological alternative for upper urinary tract obstruction. Contemp. Urol. 3, 19-26 (1991).
3. Lawrentschuk N, Russel JM. Ureteric stenting 25 years on: routine or risky? ANZ J. Surg. 74, 243-247 (2004).
4. Yachia D. Recent advances in ureteral stents. Curr. Opin. Urol. 18(2), 241-246 (2008).
5. Nabi G, Cook J, N'Dow J, Clinton S. Outcomes of stenting after uncomplicated ureteroscopy: systematic review and meta-analysis. BMJ 334, 572 (2007).
6. El-Assmy A, El-Nahas AR, Sheiz KZ. Is preshock wave lithotripsy stenting necessary for ureteral stenting necessary for ureteral stones with moderate or severe hydronephrosis? J. Urol. 176, 2059-2062 (2006).
7. Sigman DB, Del Pizzo JJ, Sklar GN. Endoscopic retrograde stenting for allograft hydronephrosis. J. Endourol. 13, 21-25 (1999).
8. Gerrard ER Jr, Burns JR, Young CJ et al. Retrograde stenting for obstruction of the renal transplant ureter. Urology 66, 256-260 (2005).
9. Agarwal G, Palagri AV, Bouiller JA, Cummings JM. Endoscopic management of ureteral complications following renal transplantation. Transplant. Proc. 38, 2921-2922 (2006).
10. White MA, Kepros JP, Zuckerman LJ. Bilateral partial ureteropelvic junction disruption after blunt trauma treated with indwelling ureteral stents. Urology 69, 384 E15-E17 (2007).
11. Chang R, Marshall FF, Mitchell S. Percutaneous management of benign ureteral strictures and fistulas. J. Urol. 137, 1126-1131 (1987).
12. Chung SY, Stein RJ, Landsittel D et al. 15-year experience with the management of extrinsic ureteral obstruction with indwelling ureteral stents. J. Urol. 172, 592-595 (2004).
13. Ganatra AM, Loughling KM. The management of malignant ureteral obstruction treated with ureteral stents. J. Urol. 174, 2125-2128 (2006).
14. Hafron J, Ost MC, Jit Tan B et al. Novel dual-lumen ureteral stents provide better ureteral flow than single ureteral stent in ex vivo porcine kidney model of extrinsic ureteral obstruction. Urology 68, 911-915 (2006).
15. Liatsikos EN, Karnabatidis D, Kagadis GC et al. Metal stents in the urinary tract. EAU-EBU Update Series 5, 77-88 (2007).
16. Liatsikos EN, Kagadis GC, Karnabatidis D et al. Application of self-expandable metal stents for ureteroileal anastomotic strictures: long-term results. J. Urol. 178, 169-173 (2007).
17. Barbalias GA, Liatsikos EN, Kagadis GC et al. Ureteropelvic junction obstruction: an innovative approach combining metallic stenting and virtual endoscopy. J. Urol. 168, 2383-2386 (2002).
18. Candela JV, Bellman GC. Ureteral stents impact of diameter and composition on patient symptoms. J. Endourol. 11, 45-47 (1997).
19. Rane A, Saleemi A, Cahill D et al. Have stent symptoms anythong to do with placement technique? J. Endourol. 15, 741-745 (2001).
20. Thomas R. Indwelling ureteral stents: impact of material and shape on patient discomfort. J. Endourol. 7, 137-140 (1993).
21. Beddingfield R, Pedro RN, Hinck B, Kreidberg C, Feia K, Monga M. Alfuzosin to relieve stent related discomfort: a prospective randomized, placebo controlled study. J. Urol. 181(1), 170-176 (2009).
22. Puri R, Murray KH. Triradiate graspers for removal of retained ureteric stents. Br. J. Urol. 73, 314-315 (1994).
23. Chin JL, Denstedt JD. Retrieval of proximally migrated ureteral stents. J. Urol. 148, 1205-1206 (1992).
24. Barbalias GA, Liatsikos EN, Kalogeropoulos C et al. Externally coated ureteral metallic stents: an unfavorable clinical experience. Eur. Urol. 42, 276-280 (2002).
25. Costerton JW, Cheng KJ, Geesey GG et al. Bacterial biofilms in nature and disease. Annu. Rev. Microbiol. 41, 435-464 (1987).
26. Tunney MM, Jones DS, Gorman PS. Biofilms and biofilm-related encrustation on ureteric stents. Meth. Enzymol. 310, 558-566 (1999).
27. Choong S, Wood S, Fry C, Whitfield H. Catheter associated urinary tract infection and encrustation. Int. J. Antimicrob. Agents 17, 305-310 (2001).
28. Hemikoglu B, Men S, Pinar A et al. Urothelial hyperplasia complicating use of metal stents in malignant ureteral obstruction. Eur. Radiol. 6, 675-681 (1996).
29. Tunney MM, Keane PF, Jones DS, Gorman SP. Comparative assessment of ureteral stent biomaterial encrustation. Biomaterials 17, 1541-1546 (1996).
30. Pauer W, Lugmayr H. Metallic Wallstents: a new therapy for extrinsic ureteral obstruction. J. Urol. 148, 281-284 (1992).
31. Desgrandchamps F, Tuchschmid Y, Cochand-Priollet B, Therin M, Teillac P, Le Duc A. Experimental study of Wallstent self-expandable metal stent in ureteral implantation. J. Urol. 9, 477-481 (1995).
32. Thijssen AM, Millward SF, Mai KT. Ureteral response to the placement of metallic stents: an animal model. J. Urol. 151, 268-270 (1994).
33. Barbalias GA, Siablis D, Liatsikos EN et al. Metal stents: a new treatment of malignant ureteral obstruction. J. Urol. 158, 54-58 (1997).
34. Lugmayr HF, Pauer W. Wallstents for the treatment of extrinsic malignant ureteral obstruction: midterm results. Radiology 198, 105-108 (1996).
35. Lugmayr HF, Pauer W. Self-expanding metal stents for palliative treatment of malignant ureteral obstruction. AJR Am. J. Roentgenol. 159, 1091-1094 (1992).
36. Barbalias GA, Liatsikos EN, Kalogeropoulou C, Karnabatidis D, Siablis D. Metallic stents in gynecologic cancer an approach to treat extrinsic ureteral obstruction. Eur. Urol. 38, 35-40 (2000).
37. Flueckiger F, Lammer J, Klein GE et al. Malignant ureteral obstruction: preliminary results of treatment with metallic self-expandable stents. Radiology 186, 169-173 (1993).
38. Lennon Gm, Thornhill JA, Sweeney PA et al. 'Firm' versus 'soft' double pigtail ureteric stents: a randomised blind comparative trial. Eur. Urol. 28, 1-5 (1995).
39. Dunn MD, Portis AJ, Kahn SA et al. Clinical effectiveness of a new stent design. Randomised single-blinded comparison of tail and double-pigtail stents. J. Endourol. 14, 195-202 (2000).
40. Joshi HB, Okeke A, Newns N et al. Characterization of urinary symptoms in patients with ureteral stents. Urology 59(4), 511-516 (2002).
41. Roemer FD. There isn't an ideal smooth-surface material yet: the history and future of urologic materials. J. Endourol. 14, 1-4 (2000).
42. Beiko DT, Knudsen BE, Watterson JD et al. Urinary tract biomaterials. J. Urol. 171, 2438-2444 (2004).
43. Marx M, Bettmann MA, Bridge S et al. The effects of various indwelling ureteral catheter materials on the normal canine ureter. J. Urol. 139, 180 (1988).
44. Denstedt JD, Wollin TA, Reid G. Biomaterials used in urology: current issued of biocompatibility, infection and encrustation. J. Endourol. 12, 493 (1998).
45. Yossepowitch O, Lifshitz DA, Dekel Y et al. Predicting the success of retrograde stenting for managing ureteral obstruction. J. Urol. 166(5), 1746-1749 (2001).
46. Wenzler DL, Kim SP, Rosevear HM et al. Success of ureteral stents for intrinsic ureteral obstruction. J. Endourol. 22(2), 295-299 (2008).
47. Rosevear HM, Kim SP, Wenzler DL et al. Retrograde ureteral stents for extrinsic ureteral obstruction: nine years experience at University of Michigan. Urology 70(5), 846-850 (2007).
48. Hao P, Li W, Song C et al. Clinical evaluation of double-pigtail stent in patients with upper urinary tract diseases: report of 2685 cases. J. Endourol. 22(1), 65-70 (2008).
49. Monga M, Pedro RN, Kriedberg C et al. Wire-based ureteral stents: impact on tensile strength and compression. Urology 70(Suppl. 3A), 52 (2007).
50. Rapp DE, Laven BA, Steinberg GD, Gerber GS. Percutaneous placement of permanent metal stents for treatment of ureteroenteric anastomotic strictures. J. Endourol. 18, 677-681 (2004).
51. Pollak JS, Rosenblatt MM, Egglin TK et al. Treatment of ureteral obstruction with the Wallstent endoprothesis: preliminary results. J. Vasc. Interv. Radiol. 6, 417-425 (1995).
52. Kurzer E, Leveille RJ. Endoscopic management of ureterointestinal strictures after radical cystectomy. J. Endourol. 19, 677-682 (2005).
53. Barbalias GA, Liatsikos EN, Karnabatidis D et al. Ureteroileal anastomotic strictures: an innovative approach with metallic stents. J. Urol. 160(4), 1270-1273 (1998).
54. Sanders R, Bissada NK, Bielshy S. Ureteroenteric anastomotic strictures: treatment with Palmaz permanent indwelling stents. J. Urol. 150, 469-470 (1993).
55. Reinberg Y, Ferrai H, Gonzalez R et al. Intraureteral metallic slef-expanding endoprothesis (Wallstent) in the treatment of difficult ureteral strictures. J. Urol. 151, 1619-1622 (1994).
56. Pallascak P, Bouchareb M, Zachoval R et al. Treatment of benign ureterointestinal anastomotic strictures with permanent ureteral Wallstent after Camey and Wallace urinary diversion: long-term follow-up. J. Endourol. 15, 575-580 (2001).
57. Gort HB, Mali WP, van Waes PF et al. Metallic self-expandable stenting of a ureteroileal stricture [letter]. AJR Am. J. Roentgenol. 155, 422 (1990).
58. Daskalopoulos G, Hatzidakis A, Triantafyllou T et al. Intraureteral metallic endoprothesis in the treatment of ureteral strictures. Eur. J. Radiol. 39, 194-200 (2001).
59. Kulkarni RP, Bellamy EA. A new thermo-expandable shape-memory nickel-titanium alloy stent for the management of ureteric strictures. BJU Int. 83, 755-759 (1999).
60. Kulkarni RP, Bellamy EA. Nickel-titanium shape-memory alloy memokath 051 ureteral stent for managing long term ureteral obstruction: 4-year experience. J. Urol. 166, 1750-1754 (2001).
61. Klarskov P, Nordling J, Nielsen JB. Experience with Memokath 051 ureteral stent. Scand. J. Urol. Nephrol. 39, 169-172 (2005).
62. Li X, He Z, Yuan J et al. Long-term results of permanent metallic stent implantation in the treatment of benign upper urinary tract occlusion. Int. J. Urol. 14, 693-698 (2007).
63. Chung H-H, Lee SH, Cho SB et al. Comparison of a new polytetrafluoroethylene-covered metallic stent to a noncovered stent in canine ureters. Cardiovasc. Intervent. Radiol. 31, 619-628 (2008).
64. Borin JF, Melamud O, Clayman RV. Initial experience with full-length metal stent to relieve malignant ureteral obstruction. J. Endourol. 20, 300-304 (2006).
65. Wah TM, Irving HC, Cartledge J. Initial experience with the Resonance metallic stent for antegrade ureteric stenting. Cardiovasc. Intervent. Radiol. 30, 705-710 (2007).
66. Nagele U, Kuczyk MA, Horstmann M et al. Initial clinical experience with full-length metal ureteral stents for obstructive ureteral stenosis. World J. Urol. 26(3), 257-262 (2008).
67. Blaschko SD, Deane LA, Krebs A et al. In vivo evaluation of flow characteristics of novel metal stent. J. Endourol. 21, 780-783 (2007).
68. Liatsikos E, Kallidonis P, Kyriazis I et al. Metallic double pigtail ureteral stents usage during extracorporeal shock wave lithotripsy in the swine model: is there any effect on the ureter? J. Endourol. DOI: 10.1089/end.2008.0569 (2008) (Epub ahead of print).
69. Liatsikos E, Kyriazis I, Kallidonis P et al. Ureteral response to abdominal radiotherapy and metallic double pigtail ureteral stents-pig model. BJU Int. (2008) (Epub ahead of print).
70. Liatsikos E, Kallidonis P, Kyriazis I et al. Ureteral obstruction: is the full metallic double pigtail stent the way to go? Eur. Urol. DOI: 10.1016/j.eururo.2009.02.004 (2009) (Epub ahead of print).
71. Buchholz NNP, Cannaby C, Fong R et al. A new SWL titanium stent (Zebra stent): resistance to shock wave exposure. J. Endourol. 19(5), 584-588 (2005).
72. Staios D, Patel M, Papatsoris A et al. Material fatigue testing a new intraureteral wire stent (Zebrastent). J. Endourol. 22(6), 1389-1393 (2008).
73. Strickler DJ, Evans A, Morris N et al. Strategies for the control of catheter encrustation. Int. J. Antimicrob. Agents 19, 499-506 (2002).
74. Tunney MM, Gorman SP. Evaluation of a poly(vinyl pyrrolidone)-coated biomaterial for urological use. Biomaterials 23, 4603-4608 (2002).
75. Tenke P, Riedl CP, Jones GL et al. Bacterial biofilm formation on urologic devices and heparin coating as preventive study. Int. J. Antimicrob. Agents 23(Suppl. 1), S67-S74 (2004).
76. Riedl CR, Witkowski M, Plas E et al. Heparin coating reduces encrustation of ureteral stents: a preliminary report. Int. J. Antimicrob. Agents 19, 507-510 (2002).
77. Cauda F, Cauda V, Fiori C et al. Heparin coating on ureteral double-J stents prevents encrustations: an in vivo case study. J. Endourol. 22(3), 465-472 (2008).
78. Multanen M, Tammela TL, Laurila M et al. Biocompatibility, encrustation and biodegradation of ofloxacin and silver nitrate coated poly-l-lactic acid stents in rabbit urethra. Urol. Res. 30, 227-232 (2002).
79. Watterson JD, Cadieux PA, Beiko DT et al. Oxalate-degrading enzymes from Oxalobacter formigenes: a novel device coating to reduce urinary tract biomaterial-related encrustation. J. Endourol. 17, 269-274 (2003).
80. Isotalo T, Tammela TL, Talja M et al. A bioabsorbable self-expandable, self-reinforced poly-l-lactic acid urethral stent for recurrent urethral strictures: a preliminary report. J. Urol. 160, 2033-2036 (1998).
81. Isotalo T, Talja M, Valimaa T et al. A bioabsorbable self-expandable, self-reinforced poly-l-lactic acid urethral stent for recurrent urethral strictures: long-term results. J. Endourol. 16, 759-762 (2002).
82. Isotalo T, Halasz A, Talja A et al. Tissue biocompatibility of a new caprolactone coated self-reinforced self-expandable poly-L-lactic acid (SR-PLLA) bioabsorbable urethral stent. J. Endourol. 13, 525-530 (1999).
83. Olweny EO, Landman J, Andreoni C et al. Evaluation of the use of a biodegradable ureteral stent after retrograde endopyelotomy in a porcine model. J. Urol. 167, 2198-2202 (2002).
84. Auge BK, Ferraro RF, Madenjian AR et al. Evaluation of a dissolvable ureteral drainage stent in a swine model. J. Urol. 168, 808-812 (2002).
85. Lingeman JE, Preminger GM, Berger Y et al. Use of a temporary ureteral drainage after uncomplicated uretesoscopy: results from a Phase II clinical trial. J. Urol. 169, 1682-1688 (2003).
86. Tajla M, Multanen M, Valimaa T et al. Bioabsorbable SR-PLGA horn stent after antegrade endopyelotomy: a case report. J. Endourol. 16(5), 299-302 (2002).
87. Kotsar A, Isotalo T, Mikkonen J et al. A new biodegradable braided self-expandable PLGA prostatic stent: an experimental study in the rabbit. J. Endourol. 22(5), 10065-10069 (2008).
88. Chew BN, Cadieux PA, Reid G et al. In vitro activity of triclosan-eluting ureteral stents against common uropathogens. J. Endourol. 20(11), 949-958 (2006).
89. Cadieux PA, Chew BN, Knudsen BE et al. Triclosan loaded ureteral stents decrease proteus mirabilis 296 infection in a rabbit urinary tract infection model. J. Urol. 175(6), 2331-2335 (2006).
90. Kukreja N, Onuma Y, Daemen J et al. The future of drug-eluting stents. Pharmacol. Res. 57, 171-180 (2008).
91. Liatsikos EN, Karnabatidis D, Kagadis GC et al. Application of paclitaxel-eluting metla mesh stents within the pig ureter: an experimental study. Eur. Urol. 51, 217-223 (2007).
92. Shin JH, Song HY, Choi CG et al. Tissue hyperplasia: influence of a paclitaxel-eluting covered stent-preliminary study in a canine urethral model. Radiology 234, 438-444 (2005).
93. Antimisiaris SG, Siamblis D, Liatsikos E et al. Liposome-coated metal stents: an in vitro evaluation of controlled-released modality in the ureter. J. Endourol. 14, 743-747 (2000).
94. Koromila G, Michanetzis GPA, Missirlis YF et al. Heparin incorporating liposomes as a delivery system of heparin from PET-covered metallic stents: effect on haemocompatibility. Biomaterials 27, 2525-2533 (2006).
95. Antimitsiaris SG, Koromila G, Michanetzis G, Missirlis YF. Liposome coated stents: a method to deliver drugs to the site of action and improve stent blood-compatibility. J. Liposome Res. 16, 303-309 (2006).
96. Kastrati A, Mehilli J, Pache J et al. Analysis of 14 trials comparing sirolimus-eluting stents with bare-metal stents. N. Engl. J. Med. 356, 1030-1039 (2007).
97. Spaulding C, Daemen J, Boersma E, Cutlip DE, Serruys PW. A pooled analysis of data comparing sirolimus-eluting stents with bare-metal stents. N. Engl. J. Med. 356, 989-997 (2007).
98. Grube E, Dawkins KD, Guagliumi G et al. TAXUS VI 2-year follow-up: randomized comparison of polymer-based paclitaxel-eluting with bare metal stents for treatment of long, complex lesions. Eur. Heart J. 28, 2578-2582 (2007).
99. Beijk MA, Neumann FJ, Wiemer M et al. Two-year results of a durable polymer everolimus-eluting stent in de novo coronary narrowing (The SPIRIT FIRST Trial). EuroIntervention 3, 206-212 (2007).
100. Miyazawa A, Ako J, Hongo Y et al. Comparison of vascular response to zotarolimus-eluting stent versus sirolimus-eluting stent: intravascular ultrasound results from ENDEAVOR III. Am. Heart J. 155, 108-113 (2008).
101. Aoki J, Ong ATL, Abizaid A et al. One-year clinical outcome of various doses and pharmacokinetic release formulations of paclitaxel eluted from an erodable polymer-insight in the paclitaxel in-stent controlled elution study (PISCES). EuroIntervention 1, 165-172 (2005).
102. Serruys PW, Sianos G, Abizaid A et al. The effect of variable dose and release kinetics on neointimal hyperplasia using a novel paclitaxel-eluting stent platform: the paclitaxel in-stent controlled elution study (PISCES). J. Am. Coll. Cardiol. 46, 253-260 (2005).
103. Grube E, Buellesfeld L, Neumann FJ et al. Six-month clinical and angiographic results of a dedicated drugeluting stent for the treatment of coronary bifurcation narrowings. Am. J. Cardiol. 99, 1691-1697 (2007).
104. Evans LW, Doran P, Marco P. XTENT® custom NXTM drug eluting stent systems. EuroIntervention 3, 158-161 (2007).
105. Ge J, Qian J, Wang X et al. Effectiveness and safety of the sirolimus-eluting stents coated with bioabsorbable polymer coating in human coronary arteries. Catheter. Cardiovasc. Interv. 69, 198-202 (2007).
106. Lee CH, Lim J, Low A et al. Sirolimus-eluting, bioabsorbable polymer-coated constant stent (Cura) in acute ST-elevation myocardial infarction: a clinical and angiographic staudy (CURAMI registry). J. Invasive. Cardiol. 19, 182-185 (2007).
107. Vranckx P, Serruys PW, Gambhir S et al. Biodegradable-polymer-based, paclitaxel-eluting Infinnium™ stent: 9-month clinical and angiographic follow-up results from the SIMPLE II prospective multi-centre registry study. EuroIntervention 2, 310-317 (2006).
108. Wessely R, Hausleiter J, Michaelis C et al. Inhibition of neointima formation by a novel drug-eluting stent system that allows for dose-adjustable, multiple, and on-site stent coating. Arterioscler. Thromb. Vasc. Biol. 25, 748-753 (2005).
109. Mehilli J, Kastrati A, Wessely R et al. For the Intracoronary Stenting and Angiographic Restenosis-Test Equivalence Between 2 Drug-Eluting Stents (ISAR-TEST) trial investigators. Randomized trial of a nonpolymer-based rapamycin-eluting stent versus a polymer-based paclitaxel-eluting stent for the reduction of late lumen loss. Circulation 113, 273-279 (2006).
110. Kollum M, Farb A, Schreiber R et al. Particle debris from a nanoporous stent coating obscures potential antiproliferative effects of tacrolimus-eluting stents in a porcine model of restenosis. Catheter. Cardiovasc. Interv. 64, 85-90 (2005).
111. Grube E, Hauptmann K-E, Buellesfeld L, Lim V, Abizaid A. Six-month results of a randomized study to evaluate safety and efficacy of a biolimus A9 eluting stent with a biodegradable polymer coating. EuroIntervention 1, 53-57 (2005).
112. Costa RA, Lansky AJ, Abizaid A et al. Angiographic results of the first human experience with the biolimus A9 drug-eluting stent for de novo coronary lesions. Am. J. Cardiol. 98, 443-446 (2006).
113. Morice M-C, Bestehorn H-P, Carrie D et al. Direct stenting of de novo coronary stenoses with tacrolimus eluting versus carbon-coated carbostents. The randomized JUPITER II trial. EuroIntervention 2, 45-52 (2006).
114. Tanimoto S, van der Giessen W, van Beusekom H et al. MAHOROBATM: Kaneka's tacrolimus eluting coronary stent. EuroIntervention 3, 149-153 (2007).
115. Aoki J, Serruys PW, van Beusekom H et al. Endothelial progenitor cell capture by stents coated with antibody against CD34: the HEALING-FIM (Healthy Endothelial Accelerated Lining Inhibits Neointimal Growth-First In Man) registry. J. Am. Coll. Cardiol. 45, 1574-1579 (2005).
116. Duckers HJ, Silber S, Winter RD et al. Circulating endothelial progenitor cells predict angiographic and intravascular ultrasound outcome following percutaneous coronary interventions in the HEALING-II trial: evaluation of an endothelial progenitor cell capturing stent. EuroIntervention 3, 67-75 (2007).
117. Duckers HJ, Soulli'e T, Heijer PD et al. Accelerated vascular repair following percutaneous coronary intervention by capture of endothelial progenitor cells promotes regression of neointimal growth at long term follow-up: final results of the Healing II trial using an endothelial progenitor cell capturing stent (Genous R stent™). EuroIntervention 3, 350-358 (2007).
118. Tanimoto S, Serruys PW, Thuesen L et al. Comparison of in vivo acute stent recoil between the bioabsorbable everolimus-eluting coronary stent and the everolimus-eluting cobalt chromium coronary stent: insights from the ABSORB and SPIRIT trials. Catheter Cardiovasc. Interv. 70, 515-523 (2007).
119. Kukreja N, Otsuka M, van Mieghem C, Ligthart J, Sianos G, Serruys P. Biodegradable drug eluting stents: invasive and non-invasive imaging. EuroIntervention 2, 403 (2006).
120. Eggebrecht H, Rodermann J, Hunold P et al. Novel magnetic resonance-compatible coronary stent: the absorbable magnesium-alloy stent. Circulation 112, E303-E304 (2005).
121. Bose D, Eggebrecht H, Erbel R. Absorbable metal stent in human coronary arteries: imaging with intravascular ultrasound. Heart 92, 892 (2006).
122. Erbel R, Di Mario C, Bartunek J et al. Temporary scaffolding of coronary arteries with bioabsorbable magnesium stents: a prospective, non-randomised multicentre trial. Lancet 369, 1869-1875 (2007).
123. Warksman R, Pakala R, Baffour R et al. Short-term effects biocorrible iron stents in porcine coronary arteries. J. Interv. Cardiol. 21, 15-20 (2008).
124. Nakayama Y, Zhou YM, Ishibashi-Ueda H. Development of in vivo tissue-engineered autologous tissue-covered stents (biocovered stents). J. Artif. Organs 10, 171-176 (2007).